Drug Trial Radar · NCT06112756
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Nov 8, 2023
Primary completion
Aug 22, 2024
Study completion Nov 7, 2024
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat women who have sleep disturbances associated with menopause. Menopause is part of a natural aging process and happens when women's menstrual cycles, also called periods, stop. Sleep disturbances, for example, frequent waking up at night, are a common and bothersome symptom associated with menopause that affects women's quality of life. The study treatment Elinzanetant (also called BAY 3427080) is under development to treat symptoms like hot flashes which are caused by hormonal changes associated with menopause. It may block the activity of a protein that has been found to contribute to sleep disturbances. The main purpose of this study is to learn how does elinzanetant affect sleep disturbances associated with menopause as measured on a sleep test called polysomnography (PSG) as compared with placebo. For this, the researchers will analyze * change in the total number of minutes a participant wakes up at night after going to sleep after 4 weeks of treatment compared to before treatment * change in the total number of minutes a participant wakes up at night after going to sleep after 12 weeks of treatment compared to before treatment * change in the participant's total time asleep while in bed after 4 and 12 weeks of treatment compared to before treatment. The study participants will be randomly (by chance) assigned to one of two treatment groups. Dependent on the group, they will take elinzanetant or placebo for 12 weeks. Each participant will be in the study for approximately 22 weeks (plus potential washout period), including a screening phase of up to 6 weeks, 12 weeks of treatment, and a follow up phase of 4 weeks after the end of treatment. 5 visits to the study site are planned. During the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check vital signs * do sleep tests * use an electronic hand-held device to record sleep quality and hot flashes at home An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Conditions
- Sleep Disturbances Associated With Menopause
Interventions
ElinzanetantDrug
Oral
PlaceboOther
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG)Time frame: From baseline until week 4
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
Preferred Research Partners
Little Port Walter, Alaska
MomDoc Women's Health Research | Scottsdale, AZ
Scottsdale, Arizona
Diagnamics | Encinitas, CA
Encinitas, California
SDS Clinical Trials Inc
Santa Ana, California
Pacific Clinical Research Management Group LLC
Upland, California
Helix Biomedics LLC | Boynton Beach, FL
Boynton Beach, Florida
Sweet Hope Research Specialty, Inc. - Hialeah
Hialeah, Florida
PharmaDev Clinical Research Institute, LLC
Miami, Florida
Segal Trials - Women's Health & General Medicine Research Site
North Miami, Florida
Palm Beach Research center
West Palm Beach, Florida
Sleep Practitioners, LLC
Macon, Georgia
SleepCare Research Institute Inc
Stockbridge, Georgia
Brengle Family Medicine
Indianapolis, Indiana
Revive Research Institute, Inc. - Women's Health
Dearborn Heights, Michigan
Essential Women's Health Associates
Las Vegas, Nevada
Clinilabs Drug Development Corporation-Feasibility
Eatontown, New Jersey
CTI Clinical Research Center
Cincinnati, Ohio
Intrepid Research, LLC.
Cincinnati, Ohio
Bogan Sleep Consultants, LLC
Columbia, South Carolina
FutureSearch Trials of Neurology LP
Austin, Texas
Sleep Therapy and Research Center | Medical Center Drive Office
San Antonio, Texas
Road Runner Research, Ltd.
San Antonio, Texas
EMCO Privatklinik
Bad Dürrnberg, State of Salzburg, Austria
Anima Research Center
Alken, Belgium
SGS CPU
Edegem, Belgium
Pneumocare SRL
Erpent, Belgium
Universitair Ziekenhuis Leuven | Gasthuisberg Campus - Sleep Centre
Leuven, Belgium
Národní ústav duševního zdraví
Klecany, Czechia
ADVANCED SLEEP RESEARCH BERLIN Berlin
Berlin, Germany
KLIN FORSCHUNG HAMBURG GMBH Hamburg
Hamburg, Germany
SOMNI BENE INSTITUT FUR MEDIZIMISCHE FORSCHUNG & SCHLAFMEDEZIN Schwerin
Schwerin, Germany
Siteworks - Zentrum für klinische Studien Hannover
Hanover, Lower Saxony, Germany
Klinische Forschung Dresden | Dresden, Germany
Dresden, Saxony, Germany
Osrodek Medycyny Snu Instytutu Psychiatrii i Neurologii
Warsaw, Poland
EMC Instytut Medyczny SA
Wroclaw, Poland
Hospital Universitario de La Ribera | Neurophysiology and Sleep Department
Alzira, Spain
Centro Medico Teknon | Unidad de Medicina del Sueno
Barcelona, Spain
Hospital Clinico San Carlos | Neurophysiology Department - Sleep Unit - Menopause Sleep Disturbance
Madrid, Spain
Hospital Universitario HM Puerta Del Sur | Departamento de Ensayos Clinicos - Sleep Unit - Menopause Sleep Disturbance
Móstoles, Spain
Hospital Universitario de Araba | Santiago Campus - Unidad Sueno
Vitoria-Gasteiz, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.